# Sirtuin Activation with SRT3025 Reduces Cholesterol and Atherosclerosis in Mice

Canonical source: https://retacompare.com/research/sirtuin-activation-with-srt3025-reduces-cholesterol-and-atherosclerosis-in-mice

Sinclair Lab Research · 2015-01-01


    The pharmacological activation of sirtuin 1 (Sirt1) using SRT3025 shows promise in reducing cholesterol levels and atherosclerosis in a mouse model. This study is particularly relevant as it investigates the role of Sirt1 in lipid metabolism, a crucial factor in cardiovascular health, which is increasingly recognized as a significant aspect of longevity research.

 What this study examined

This study examined the effects of the Sirt1 activator SRT3025 on apolipoprotein E-deficient (Apoe(-/-)) mice, which are a well-established model for studying atherosclerosis. The mice were fed a high-cholesterol diet supplemented with SRT3025 over a 12-week period. The primary outcomes assessed included plasma levels of LDL-cholesterol, total cholesterol, and the extent of atherosclerosis, alongside the expression of key proteins involved in lipid metabolism.

 Why this matters for longevity research

The findings from this study are significant for longevity research as they highlight the potential of Sirt1 activation to influence lipid profiles and reduce atherosclerosis, conditions that are closely linked to cardiovascular disease and overall healthspan. By understanding how Sirt1 modulates lipid metabolism, researchers can explore new therapeutic avenues for extending healthspan and potentially lifespan through dietary and pharmacological interventions.

 Key findings

SRT3025 treatment decreased plasma levels of LDL-cholesterol and total cholesterol.

The treatment reduced the extent of atherosclerosis in Apoe(-/-) mice.

SRT3025 increased the deacetylation of hepatic p65 and skeletal muscle Foxo1.

The drug did not change mRNA expression of hepatic LDL receptor (Ldlr) or proprotein convertase subtilisin/kexin type 9 (Pcsk9), but increased their protein expression.

Reduced plasma levels of Pcsk9 were observed following Sirt1 activation.

In vitro, SRT3025 attenuated Pcsk9 secretion, enhancing Ldlr expression and LDL uptake.

Co-administration of exogenous Pcsk9 with SRT3025 diminished the observed effects.

 The science behind it

Sirtuins, including Sirt1, are a family of proteins that play a crucial role in cellular regulation, particularly in response to metabolic stress. They are involved in deacetylation processes that affect various substrates, including transcription factors and metabolic enzymes. The NAD+/sirtuin axis is increasingly recognized as a critical pathway in aging and longevity, influencing processes such as inflammation, metabolism, and stress resistance. In this study, SRT3025's activation of Sirt1 led to important post-translational modifications that enhanced the expression of proteins involved in lipid metabolism, suggesting a novel mechanism through which Sirt1 may exert atheroprotective effects.

 How it fits into the longevity field

This research aligns with a broader body of literature exploring the role of sirtuins in aging and metabolic health. Other interventions, such as caloric restriction and exercise, have also been shown to activate sirtuins and improve healthspan. The findings from this study contribute to the understanding of how pharmacological agents targeting the sirtuin pathway may serve as potential therapies for age-related diseases, particularly those related to cardiovascular health.

 Practical takeaways

Researchers and informed readers should consider the implications of Sirt1 activation in the context of cardiovascular health and longevity. The results suggest that pharmacological agents like SRT3025 could be investigated further for their potential to modulate lipid metabolism and reduce atherosclerosis. However, further studies are needed to evaluate the long-term effects and safety of such interventions in humans.

 FAQ

 What is Sirt1 and why is it important?

Sirt1 is a member of the sirtuin family of proteins, which are involved in regulating cellular processes related to metabolism, stress response, and aging. Its activation is associated with beneficial effects on healthspan.

 How does SRT3025 work?

SRT3025 activates Sirt1, leading to post-translational modifications that enhance the expression of proteins involved in lipid metabolism, thereby reducing cholesterol levels and atherosclerosis.

 What are the implications of this study for human health?

The study suggests that pharmacological activation of Sirt1 may offer a new approach to managing cholesterol levels and reducing cardiovascular disease risk, highlighting the need for further research in human trials.

 Source: PubMed · Eur Heart J · published 2015-01-01.

## Sources

- PubMed · Eur Heart J: https://pubmed.ncbi.nlm.nih.gov/24603306/